Vera Therapeutics VERA Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vera Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vera Therapeutics's financing cash flow?
- Vera Therapeutics (VERA) reported financing cash flow of $3.94M in Q1 2026.
- How has Vera Therapeutics's financing cash flow changed year-over-year?
- Vera Therapeutics's financing cash flow increased by 157.1% year-over-year, from $1.53M to $3.94M.
- What is the long-term trend for Vera Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Vera Therapeutics's financing cash flow has grown at a 54.7% compound annual growth rate (CAGR), from $53.88M to $308.9M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.